173 related articles for article (PubMed ID: 21735097)
21. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
22. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
23. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
24. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.
Gyenis L; Kuś A; Bretner M; Litchfield DW
J Proteomics; 2013 Apr; 81():70-9. PubMed ID: 23017496
[TBL] [Abstract][Full Text] [Related]
25. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
26. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
27. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
28. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
29. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
Deepa P; Thirumeignanam D; Kolandaivel P
J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
[TBL] [Abstract][Full Text] [Related]
30. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
33. A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors.
Martín-Acosta P; Haider S; Amesty Á; Aichele D; Jose J; Estévez-Braun A
Eur J Med Chem; 2018 Jan; 144():410-423. PubMed ID: 29288942
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Bdzhola VG; Sapelkin VM; Zien P; Yarmoluk SM
J Med Chem; 2006 Nov; 49(22):6443-50. PubMed ID: 17064064
[TBL] [Abstract][Full Text] [Related]
35. In Silico and In Vitro Studies of Natural Compounds as Human CK2 Inhibitors.
Haidar S; Jürgens F; Aichele D; Jose J
Curr Comput Aided Drug Des; 2021; 17(2):323-331. PubMed ID: 32160849
[TBL] [Abstract][Full Text] [Related]
36. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
37. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
38. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
Bollacke A; Nienberg C; Borgne ML; Jose J
J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
[TBL] [Abstract][Full Text] [Related]
39. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
40. Multisite-directed inhibitors of protein kinase CK2: new challenges.
Świder R; Masłyk M; Martín-Santamaría S; Ramos A; de Pascual-Teresa B
Mol Cell Biochem; 2011 Oct; 356(1-2):117-9. PubMed ID: 21750979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]